Document is current
Any future updates will be listed below
-
Authors
Pfister, Dominik https://orcid.org/0000-0002-0542-2638
Núñez, Nicolás Gonzalo https://orcid.org/0000-0003-3837-270X
Pinyol, Roser
Govaere, Olivier https://orcid.org/0000-0002-4426-6930
Pinter, Matthias
Szydlowska, Marta https://orcid.org/0000-0002-4660-899X
Gupta, Revant https://orcid.org/0000-0002-0881-5074
Qiu, Mengjie
Deczkowska, Aleksandra https://orcid.org/0000-0003-0844-4346
Weiner, Assaf
Müller, Florian
Sinha, Ankit
Friebel, Ekaterina https://orcid.org/0000-0003-1419-2376
Engleitner, Thomas
Lenggenhager, Daniela https://orcid.org/0000-0002-5382-9854
Moncsek, Anja https://orcid.org/0000-0002-1191-5842
Heide, Danijela
Stirm, Kristin
Kosla, Jan
Kotsiliti, Eleni
Leone, Valentina
Dudek, Michael
Yousuf, Suhail
Inverso, Donato https://orcid.org/0000-0003-0987-3345
Singh, Indrabahadur
Teijeiro, Ana
Castet, Florian
Montironi, Carla
Haber, Philipp K.
Tiniakos, Dina
Bedossa, Pierre
Cockell, Simon
Younes, Ramy
Vacca, Michele https://orcid.org/0000-0002-1973-224X
Marra, Fabio https://orcid.org/0000-0001-8629-0878
Schattenberg, Jörn M.
Allison, Michael https://orcid.org/0000-0003-3677-3294
Bugianesi, Elisabetta
Ratziu, Vlad
Pressiani, Tiziana
D’Alessio, Antonio https://orcid.org/0000-0002-9164-3671
Personeni, Nicola https://orcid.org/0000-0002-7995-272X
Rimassa, Lorenza https://orcid.org/0000-0001-9957-3615
Daly, Ann K.
Scheiner, Bernhard
Pomej, Katharina https://orcid.org/0000-0002-2807-3565
Kirstein, Martha M.
Vogel, Arndt
Peck-Radosavljevic, Markus https://orcid.org/0000-0002-0597-2728
Hucke, Florian
Finkelmeier, Fabian
Waidmann, Oliver
Trojan, Jörg
Schulze, Kornelius
Wege, Henning
Koch, Sandra
Weinmann, Arndt
Bueter, Marco
Rössler, Fabian
Siebenhüner, Alexander
De Dosso, Sara
Mallm, Jan-Philipp https://orcid.org/0000-0002-7059-4030
Umansky, Viktor
Jugold, Manfred
Luedde, Tom
Schietinger, Andrea https://orcid.org/0000-0003-3644-1687
Schirmacher, Peter
Emu, Brinda
Augustin, Hellmut G. https://orcid.org/0000-0002-7173-4242
Billeter, Adrian
Müller-Stich, Beat
Kikuchi, Hiroto https://orcid.org/0000-0002-3601-8435
Duda, Dan G. https://orcid.org/0000-0001-7065-8797
Kütting, Fabian
Waldschmidt, Dirk-Thomas
Ebert, Matthias Philip
Rahbari, Nuh
Mei, Henrik E. https://orcid.org/0000-0003-0697-7755
Schulz, Axel Ronald https://orcid.org/0000-0002-5106-0148
Ringelhan, Marc https://orcid.org/0000-0003-3131-5657
Malek, Nisar
Spahn, Stephan
Bitzer, Michael
Ruiz de Galarreta, Marina
Lujambio, Amaia https://orcid.org/0000-0002-2798-1481
Dufour, Jean-Francois https://orcid.org/0000-0002-8062-1346
Marron, Thomas U.
Kaseb, Ahmed
Kudo, Masatoshi https://orcid.org/0000-0002-4102-3474
Huang, Yi-Hsiang
Djouder, Nabil https://orcid.org/0000-0001-8423-1030
Wolter, Katharina
Zender, Lars https://orcid.org/0000-0001-7626-2849
Marche, Parice N.
Decaens, Thomas
Pinato, David J. https://orcid.org/0000-0002-3529-0103
Rad, Roland https://orcid.org/0000-0002-6849-9659
Mertens, Joachim C. https://orcid.org/0000-0003-2007-0308
Weber, Achim https://orcid.org/0000-0003-0073-3637
Unger, Kristian
Meissner, Felix https://orcid.org/0000-0003-1000-7989
Roth, Susanne
Jilkova, Zuzana Macek
Claassen, Manfred
Anstee, Quentin M.
Amit, Ido https://orcid.org/0000-0003-2968-877X
Knolle, Percy https://orcid.org/0000-0003-2983-0414
Becher, Burkhard https://orcid.org/0000-0002-1541-7867
Llovet, Josep M. https://orcid.org/0000-0003-0547-2667
Heikenwalder, Mathias https://orcid.org/0000-0002-3135-2274
- License Information
-
More Information
Article History
Received: 17 February 2020
Accepted: 16 February 2021
First Online: 24 March 2021
Change Date: 6 April 2021
Change Type: Update
Change Details: An amendment to the underlying article code was made to enable an author name to appear correctly in PubMed.
Competing interests
: M.P. is an investigator for Bayer, BMS, Lilly, and Roche; has received speaker honoraria from Bayer, BMS, Eisai, Lilly, and MSD; is a consultant for Bayer, BMS, Eisai, Ipsen, Lilly, MSD, and Roche; and has received travel support from Bayer and BMS. D.P. works currently for Novo Nordisk. M. Szydlowksa works currently for Astra Zeneca. M.K. received honoraria from BMS as consultant and is an investigator for AstraZeneca and BMS. A.V. has served as consultant for Roche, Bayer, Lilly, BMS, Eisai, and Ipsen; has received speaking fees form Roche, Bayer, Lilly, BMS, Eisai, and Ipsen; and is an investigator for Roche, Bayer, Lilly, BMS, Eisai, and Ipsen. F.H. has received travel support from Bayer, Abbvie, and Gilead. M.P.-R. is an advisor/consultant for Astra Zeneca, Bayer, BMS, Eisai, Ipsen, Lilly, and MSD; has served as a speaker for Bayer, Eisai, and Lilly; and is an investigator for Bayer, BMS, Exelixis, and Lilly. F.F. has received travel support from Abbvie and Novartis. O.W. has served as consultant for Amgen, Bayer, BMS, Celgene, Eisai, Merck, Novartis, Roche, Servier, and Shire; has served as a speaker for Abbvie, Bayer, BMS, Celgene, Falk, Ipsen, Novartis, Roche, and Shire; and has received travel support from Abbvie, BMS, Ipsen, Novartis, and Servier. J.T. has served as consultant for Amgen, Bayer, BMS, Eisai, Lilly, Merck Serono, MSD, Ipsen, and Roche; has received travel support from BMS and Ipsen; has received speaking fees from Amgen, Bayer, BMS, Eisai, Lilly, Merck Serono, MSD, Ipsen, and Roche; and is an investigator for Amgen, Bayer, BMS, Eisai, Lilly, Merck Serono, MSD, Ipsen, and Roche. K.S. has served as consultant for Ipsen and Bayer; and conducts studies for Bayer, Roche, Lilly, MSD, and BMS. H.W. has served as speaker for Bayer, Eisai, and Ipsen; has served as a consultant for Bayer, Eisai, Lilly, BMS, Roche, and Ipsen; and conducts studies for Bayer, Roche, Lilly, MSD, and BMS. A. Weberis an advisor for BMS, Wako, Eisai, Roche, and Amgen. J.C.M. has received consulting honoraria from Abbvie, Bayer, BMS, Eisai, Gilead, Incyte, Intercept and MSD for work performed outside the current study. J.M.L. is receiving research support from Bayer HealthCare Pharmaceuticals, Eisai Inc, Bristol-Myers Squibb, Boehringer-Ingelheim and Ipsen, and consulting fees from Eli Lilly, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb, Eisai Inc, Celsion Corporation, Exelixis, Merck, Ipsen, Genentech, Roche, Glycotest, Leerink Swann LLC, Fortress Biotech, Nucleix, Can-Fite Biopharma, Sirtex, Mina Alpha Ltd and AstraZeneca. J.M.S. serves as a consultant for Intercept Pharmaceuticals, Genfit, Gilead Sciences, BMS, Madrigal, Novartis, Pfizer, Roche, and Siemens-Healthineers; and has received research funding from Gilead Sciences. D.J.P. has received lecture fees from ViiV Healthcare and Bayer Healthcare; travel expenses from BMS and Bayer Healthcare; consulting fees from Mina Therapeutics, EISAI, Roche and Astra Zeneca; and research funding (to institution) from MSD and BMS. J.-F.D. has served on advisory committees for Abbvie, Bayer, Bristol-Myers Squibb, Falk, Genfit, Genkyotex, Gilead Sciences, HepaRegenix, Intercept, Lilly, Merck, and Novartis; and has spoken or taught at Bayer, Bristol-Myers Squibb, Intercept, Genfit, Gilead Sciences, Novartis, and Roche. L.R. has received consulting fees from Amgen, ArQule, Astra Zeneca, Basilea, Bayer, Celgene, Eisai, Exelixis, Hengrui, Incyte, Ipsen, Lilly, MSD, Nerviano Medical Sciences, Roche, and Sanofi; lectures fees from AbbVie, Amgen, Eisai, Gilead, Incyte, Ipsen, Lilly, Roche, Sanofi; travel expenses from Ipsen; and institutional research funding from Agios, ARMO BioSciences, AstraZeneca, BeiGene, Eisai, Exelixis, Fibrogen, Incyte, Ipsen, Lilly, MSD, and Roche. N.P. has received consulting fees from Amgen, Merck Serono, and Servier; lectures fees from AbbVie, Gilead and Lilly; travel expenses from Amgen and ArQule; and institutional research funding from Basilea, Merck Serono and Servier. T.P. has received institutional research funding from Lilly. D.G.D. has received consultant fees from Bayer, Simcere, Surface Oncology and BMS; and research grants from Bayer, Exelixis and BMS. The remaining authors declare no competing interests.
